Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Castration-resistant Prostate Cancer|Recurrent Epithelial Ovarian Cancer|Breast Cancer
Interventions: DRUG: AsiDNA|DRUG: Olaparib
Sponsor: Valerio Therapeutics